Search

Your search keyword '"Consoli, Ugo"' showing total 248 results
Start Over Author "Consoli, Ugo"
248 results on '"Consoli, Ugo"'

1. Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi

Author

Santoro, Armando, Mazza, Rita, Spina, Michele, Califano, Catello, Specchia, Giorgina, Carella, Michele, Consoli, Ugo, Palombi, Francesca, Musso, Maurizio, Pulsoni, Alessandro, Kovalchuk, Sofya, Bonfichi, Maurizio, Ricci, Francesca, Fabbri, Alberto, Liberati, Anna Marina, Rodari, Marcello, Giordano, Laura, Chimienti, Emanuela, Balzarotti, Monica, Sorasio, Roberto, Gallamini, Andrea, Ghiggi, Chiara, Ciammella, Patrizia, Ricardi, Umberto, Chauvie, Stephane, Carlo-Stella, Carmelo, and Merli, Francesco

Published
2021
Full Text
View/download PDF

3. Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma Network.

Author

Del Fabro, Vittorio, Markovic, Uros, Frazzetto, Sara, Sciortino, Roberta, Bellofiore, Claudia, Di Giorgio, Mary Ann, Leotta, Valerio, Bulla, Anna, Curto Pelle, Angelo, Elia, Federica, Mannina, Donato, Consoli, Ugo, Mineo, Giuseppe, Giallongo, Cesarina, Romano, Alessandra, Di Raimondo, Francesco, and Conticello, Concetta

Published
2024
Full Text
View/download PDF

4. A real‐life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.

Author

Bellofiore, Claudia, Benvenuti, Pietro, Mina, Roberto, Basset, Marco, Foli, Andrea, Nanci, Martina, Nuvolone, Mario, Guida, Gianluigi, Attanasio, Andrea, Mussinelli, Roberta, Mangiacavalli, Silvia, Cartia, Claudio Salvatore, Masoni, Valeria, Palumbo, Michele, Cani, Lorenzo, Oliva, Stefania, Consoli, Ugo, Conticello, Concetta, Di Raimondo, Francesco, and Arcaini, Luca

Subjects
DARATUMUMAB, AMYLOIDOSIS, LENALIDOMIDE, MULTIPLE myeloma, BORTEZOMIB
Abstract

Daratumumab‐based regimens are the new standard of care for newly diagnosed patients with AL amyloidosis based on the results of the ANDROMEDA study. However, real‐world data on daratumumab efficacy in upfront therapy in unselected patients are scanty. In the framework of a prospective observational study, we investigated the efficacy and safety of daratumumab in 88 newly diagnosed patients, including subjects with IIIb cardiac stage (26%) or myeloma defining events (29%). Daratumumab was administered with bortezomib in 50 (56%) patients, lenalidomide in 31 (35%), and monotherapy in 7 (8%). The rate of serious adverse events was low (16%). The overall hematologic response rate was 75% with 52 (59%) patients attaining at least a very good partial response (VGPR) at six months. Amongst patients evaluable for organ response, the rate of cardiac and renal responses at 6 months was 31% and 21%, respectively. Comparing stage IIIb patients with the remaining ones, the rate of profound hematologic response was not significantly different (≥VGPR 57% vs. 59%, p 0.955) likewise the rate of cardiac (33% vs. 30%, p 0.340) and renal (40% vs. 16%, p 0.908) responses. Daratumumab‐based regimens demonstrated to be safe and effective in treatment‐naïve AL amyloidosis even in advanced stage disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Author

Gentile, Massimo, Morabito, Fortunato, Del Poeta, Giovanni, Mauro, Francesca Romana, Reda, Gianluigi, Sportoletti, Paolo, Laurenti, Luca, Coscia, Marta, Herishanu, Yair, Recchia, Anna Grazia, Varettoni, Marzia, Murru, Roberta, Chiarenza, Annalisa, Condoluci, Adalgisa, Moia, Riccardo, Pietrasanta, Daniela, Loseto, Giacomo, Consoli, Ugo, Scortechini, Ilaria, Rossi, Francesca Maria, Zucchetto, Antonella, Fraticelli, Vincenzo, Vigna, Ernesto, Botta, Cirino, Tripepi, Giovanni, Arrigo, Graziella D’, Rago, Angela, Angeletti, Ilaria, Biagi, Annalisa, Del Giudice, Ilaria, Bomben, Riccardo, Rigolin, Gian Matteo, Rossi, Davide, Di Raimondo, Francesco, Gaidano, Gianluca, Polliack, Aaron, Cuneo, Antonio, Foà, Robin, and Gattei, Valter

Published
2021
Full Text
View/download PDF

6. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Author

Bekadja, Mohamed, Hamladji, Rose-Marie, Ali, Hocine Ait, Hamdi, Selma, Touhami, Hadj, Mansour, Nourredine Sidi, Willenbacher, Wolfgang, Linkesch, Werner, Nemet, Damir, Pedersen, Robert Shou, Abildgaard, Niels, Laane, Edward, Hein, Marju, Mohty, Mohamad, Eveillard, Jean Richard, Yamani, Abderrazak el, Moreau, Philippe, Sanhes, Laurence, Lepeu, Gérard, Laribi, Kamel, Jourdan, Eric, Fitoussi, Olivier, Allangba, Olivier, Fleury, Joël, Escoffre, Martine, Benramdane, Riad, Cartron, Guillaume, Dine, Gérard, Legouffe, Eric, Harich, Hanns-Detlev, Illmer, Thomas, Dörfel, Steffen, Hannig, Carla Verena, Koenigsmann, Michael, Prange-Krex, Gabriele, Salwender, Hans, Tamm, Ingo, Zeller, Wolfgang, Maasberg, Michael, Schlag, Rudolf, Klausmann, Martine, Uhlig, Jens, Alkemper, Burkhard, Schütz, Stefan, Tessen, Hans-Werner, Mohr, Benno, Schmidt, Peter, Heinrich, Bernhard, Hebart, Holger, Seipelt, Gernot, Zoeller, Thomas, Heits, Frank, Müller-Naendrup, Clemens, Hansen, Richard, Repp, Roland, Von Weikersthal, Ludwig Fischer, Schmits, Rudolf, Heßling, Jörg, Krammer-Steiner, B., Janzen, Viktor, Schauer, Michael, Grüner, Marcus W., Kisro, Jens, Denzlinger, Claudio, Freier, Werner, Junghanss, Christian, Görner, Martin, Laichinger, Katharina, Ostermann, Helmut, Dürk, Heinz, Hess, Georg, Reich, Gernot, Terpos, Evangelos, Dimopoulos, Meletios, Matsouka, Panagiota, Pouli, Anastasia, Anagnostopoulos, Achilles, Masszi, Tamas, Borbényi, Zita, Ivanyi, Janos, Szomor, Arpad, Abadi, Uri, Nagler, Arnon, Magen, Hila, Avivi, Irit, Quitt, Miriam, Palumbo, Antonio, Boccadoro, Mario, De Stefano, Valerio, Za, Tommaso, Vallisa, Daniele, Foa, Roberto, Corso, Alessandro, Bosi, Alberto, Vacca, Angelo, Lanza, Francesco, Palazzo, Giulia, Avvisati, Giuseppe, Cavo, Michele, Ferrara, Felicetto, Consoli, Ugo, Cantonetti, Maria, Angelucci, Emanuele, Califano, Catello, Di Raimondo, Francesco, Guarini, Attilio, Musso, Maurizio, Pizzuti, Michele, Giuliani, Nicola, Ardizzoia, Antonio, Di Renzo, Nicola, Gaidano, Gianluca, Gozzetti, Alessandro, Pitini, Vincenzo, Farina, Gabriella, Centurioni, Riccardo, De Fabritiis, Paolo, Iuliano, Francesco, La Nasa, Giorgio, La Verde, Giacinto, Pane, Fabrizio, Recine, Umberto, La Targia, Maria, Mineo, Giuseppe, Cangialosi, Clotilde, Fagnani, Daniele, Federici, Augusto, Romano, Atelda, Specchia, Giorgina, Storti, Sergio, Bongarzoni, Velia, Bacigalupo, Andrea, Gobbi, Marco, Latte, Giancarlo, Mannina, Donato, Capalbo, Silvana, Lejniece, Sandra, Pečeliūnas, Valdas, Jurgutis, Mindaugas, Stankovic, Svetlana, Legiec, Wojciech, Woszczyk, Dariusz, Hołojda, Jadwiga, Gornik, Slawomir, Pluta, Andrzej, Morawiec-Szymonik, Elzbieta, Kyrcz-Krzemien, Slawomira, Homenda, Wojciech, Grosicki, Sebastian, Sulek, Kazimierz, Lange, Andrzej, Kloczko, Janusz, Starzak-Gwozdz, Jolanta, Hellmann, Andrzej, Komarnicki, Mieczyslaw, Kuliczkowski, Kazimierz, Viveiros, Carolina, Gonçalves, Cristina, Esefyeva, Natalia, Kochkareva, Julia, Kaplanov, Kamil, Volodicheva, Elena, Laricheva, Elena, Dergacheva, Valentina, Chukavina, Marina, Volchenko, Natalia, Nazarova, Irina, Anchukova, Ludmila, Ovanesova, Elena, Gritsenko, Taras, Salogub, Galina, Magomedova, Ludmila, Kuznetsova, Irina, Osyunikhina, Svetlana, Serdyuk, Olga, Karyagina, Elena, Ivanova, Valentina, Černelč, Slovenia Peter, Louw, Vernon, Coetzee, Corlia, Gunther, Karen, Moodley, Dhayanithi, Duran, Soledad, Gutiérrez, Asunción Echeveste, De Oteyza, Jaime Perez, Capote, Francisco Javier, Casanova, Maria, Sanchez, Jesus Martin, Rios-Herranz, Eduardo, Ibañez-Garcia, Jeronima, Herranz, Maria Jose, Hernandez, Belen, Sanchez, Sara Sanchez, Escalante, Fernando, Carnicero, Fernando, Lleonart, Joan Bargay, Gironella, Mercedes, Martínez, Rafael, De La Guia, Ana Lopez, Palomera, Luis, Iglesias, Rebeca, Ramos, Fernando Solano, De La Serna, Javier, Sanchez, Pedro Garcia, Vidal, Juan Besalduch, Mateos, Maria-Victoria, Morfa, Miguel Diaz, Beksac, Turkey – Meral, Vural, Filiz, Aydin, Yildiz, Unal, Ali, Goker, Hakan, Bilgir, Oktay, Guvenc, Birol, Turgut, Mehmet, Ozet, Gulsum Gulistan, Ali, Ridvan, Masliak, Zvenyslava, Kyselyova, Maryna, Glushko, Nataliia, Vybyrana, Renata, Skrypnyk, Igor, Tretyak, Natalya, Kharchevska, Tetiana, Dyagil, Iryna, Popovs'ka, Tetiana, Shimanskiy, Vadim, Lysa, Tamila, Oliynyk, Hanna, Vilchevskaya, Kateryna, Kryachok, Iryna, Popovych, Yuriy, Romanyuk, Natalia, Yushchenko, Natalia, Kaplan, Polina, Rekhtman, Grygoriy, Pylypenko, Halyna, Kozlov, Viktor, Drach, Johannes, Harousseau, Jean-Luc, Einsele, Hermann, Goldschmidt, Hartmut, Facon, Thierry, Michalet, Mauricette, Savchenko, Valery G., De la Rubia, Javier, Cook, Gordon, Mellqvist, Ulf-Henrik, Ludwig, Heinz, Beksac, Meral, Bekadja, Mohamed Amine, Durán, Maria Soledad, Kochkareva, Yulia, Berthou, Christian, Silva, João, Pedersen, Robert Schou, Černelč, Peter, Potamianou, Anna, Couturier, Catherine, Feys, Caroline, and Thoret-Bauchet, Florence

Published
2018
Full Text
View/download PDF

8. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Author

Gentile, Massimo, Martino, Enrica Antonia, Visentin, Andrea, Coscia, Marta, Reda, Gianluigi, Sportoletti, Paolo, Mauro, Francesca Romana, Laurenti, Luca, Varettoni, Marzia, Murru, Roberta, Chiarenza, Annalisa, Vigna, Ernesto, Mendicino, Francesco, Lucia, Eugenio, Bossio, Sabrina, Recchia, Anna Grazia, Moia, Riccardo, Pietrasanta, Daniela, Loseto, Giacomo, Consoli, Ugo, Scortechini, Ilaria, Rossi, Francesca Maria, Zucchetto, Antonella, Al-Janazreh, Hamdi, Vitale, Candida, Tripepi, Giovanni, D’Arrigo, Graziella, Angeletti, Ilaria, Bomben, Riccardo, Neri, Antonino, Cutrona, Giovanna, Fronza, Gilberto, Di Raimondo, Francesco, Gaidano, Gianluca, Cuneo, Antonio, Foà, Robin, Ferrarini, Manlio, Trentin, Livio, Gattei, Valter, and Morabito, Fortunato

Published
2020
Full Text
View/download PDF

9. Gaucher disease prevalence in 600 patients affected by monoclonal gammopathy of undetermined significance.

Author

Giuffrida, Gaetano, Markovic, Uros, Condorelli, Annalisa, Duminuco, Andrea, Calafiore, Valeria, Conticello, Concetta, Romano, Alessandra, Grasso, Stephanie, Riccobene, Carla, Ragusa, Marco Tindaro Valentino, Esposito, Benedetta, Nicolosi, Daniela, Calagna, Marianna, Nardo, Antonella, Consoli, Ugo, Uccello, Giuseppina, Di Giacomo, Valeria, Neri, Santo, Cingari, Maria Rocca, and Rodà, Filippo

Subjects
GLYCOGEN storage disease type II, MONOCLONAL gammopathies, GAUCHER'S disease, DISEASE prevalence, LYSOSOMAL storage diseases, PATIENT experience, DELAYED diagnosis
Abstract

Background: Gaucher disease (GD) is a rare autosomal recessive inherited disorder caused by the lysosomal enzyme acid β‐glucosidase deficiency. Many patients experience a critical delay in the diagnosis of up to 8–10 years due to its rarity and variability in signs and symptoms, with the consultation of several specialists. Patients and Methods: This prospective observational study analyzed the prevalence of GD in 600 patients with monoclonal gammopathy of uncertain significance (MGUS) from January 2018 until February 2022. Results: The mean age of participants was 66 years, with a mean monoclonal component of 0.58 g/dL. In 433 MGUS patients with available data, anemia (hemoglobin level < 10 g/dL) was present in 31 patients (7%), and thrombocytopenia (platelet count <100.000/mm3) in 24 (5.5%). Of 600 MGUS patients tested for acid β‐glucosidase enzyme activity, 7 patients (1.2%) had activity below 2.5 nmol/h/mL. In comparison, GBA gene analysis was executed in 110 patients. It revealed 4 patients (0.7%) affected by GD (3 patients with compound heterozygous mutation and 1 with homozygous mutation), with a prevalence of 1 every 150 MGUS patients. Furthermore, 12 out of the remaining 106 evaluated patients (11%) were carriers of a single heterozygous mutation while having regular enzyme activity. Conclusions: The clinical heterogeneity of GD and frequent lack of awareness among physicians often lead to diagnostic delays and severe clinical manifestations. The role of MGUS in the presence of at least one clinical sign, such as low platelet count, organomegaly, bone pain, or bleeding tendency, could aid in initiating GD screening with DBS, thus reducing the period between symptom onset and the diagnosis of this rare disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment

Author

Morabito, Fortunato, Cutrona, Giovanna, Mosca, Laura, D’Anca, Marianna, Matis, Serena, Gentile, Massimo, Vigna, Ernesto, Colombo, Monica, Recchia, Anna Grazia, Bossio, Sabrina, De Stefano, Laura, Maura, Francesco, Manzoni, Martina, Ilariucci, Fiorella, Consoli, Ugo, Vincelli, Iolanda, Musolino, Caterina, Cortelezzi, Agostino, Molica, Stefano, Ferrarini, Manlio, and Neri, Antonino

Published
2015
Full Text
View/download PDF

12. Obinutuzumab-Based Immunochemotherapy Mitigates Early Progression Risk with a Substantial 2-Year Progression-Free Survival (PFS) in Patients with Previously Untreated Advanced Follicular Lymphoma and a FLIPI Score ≥2: An Interim Analysis of the Ambispective Urban Study

Author

Pinto, Antonio, primary, Guardalben, Emanuele, additional, Caltagirone, Marco, additional, Piparo, Chiara, additional, Patti, Caterina, additional, Pennese, Elsa, additional, De Lorenzo, Sonya, additional, Pavone, Vincenzo, additional, Consoli, Ugo, additional, Piazza, Francesco, additional, Capponi, Monia, additional, Puccini, Benedetta, additional, Baldini, Luca, additional, Pulsoni, Alessandro, additional, Hohaus, Stefan, additional, Stefani, Piero Maria, additional, Santini, Simone, additional, Zilioli, Vittorio Ruggero, additional, Stelitano, Caterina, additional, Arcaini, Luca, additional, Gritti, Giuseppe, additional, Ladetto, Marco, additional, and Zinzani, Pier Luigi, additional

Published
2022
Full Text
View/download PDF

13. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers

Author

Cantoni, Silvia, Carpenedo, Monica, Mazzucconi, Maria Gabriella, De Stefano, Valerio, Carrai, Valentina, Ruggeri, Marco, Specchia, Giorgina, Vianelli, Nicola, Pane, Fabrizio, Consoli, Ugo, Artoni, Andrea, Zaja, Francesco, Dʼadda, Mariella, Visentin, Andrea, Ferrara, Felicetto, Barcellini, Wilma, Caramazza, Domenica, Baldacci, Erminia, Rossi, Elena, Ricco, Alessandra, Ciminello, Angela, Rodeghiero, Francesco, Nichelatti, Michele, and Cairoli, Roberto

Published
2018
Full Text
View/download PDF

14. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Author

Bruzzese, Antonella, primary, Derudas, Daniele, additional, Galli, Monica, additional, Martino, Enrica Antonia, additional, Rocco, Stefano, additional, Conticello, Concetta, additional, Califano, Catello, additional, Giuliani, Nicola, additional, Mangiacavalli, Silvia, additional, Farina, Giuliana, additional, Lombardo, Alessandra, additional, Brunori, Marino, additional, Rossi, Elena, additional, Antonioli, Elisabetta, additional, Ria, Roberto, additional, Zambello, Renato, additional, Di Renzo, Nicola, additional, Mele, Giuseppe, additional, Marcacci, Gianpaolo, additional, Pietrantuono, Giuseppe, additional, Palumbo, Gaetano, additional, Cascavilla, Nicola, additional, Cerchione, Claudio, additional, Belotti, Angelo, additional, Criscuolo, Clelia, additional, Uccello, Giuseppina, additional, Curci, Paola, additional, Vigna, Ernesto, additional, Mendicino, Francesco, additional, Iaccino, Enrico, additional, Mimmi, Selena, additional, Botta, Cirino, additional, Vincelli, Donatella, additional, Sgherza, Nicola, additional, Bonalumi, Angela, additional, Cupelli, Luca, additional, Stocchi, Raffaella, additional, Martino, Massimo, additional, Ballanti, Stelvio, additional, Gangemi, Dominella, additional, Gagliardi, Alfredo, additional, Gamberi, Barbara, additional, Pompa, Alessandra, additional, Tripepi, Giovanni, additional, Frigeri, Ferdinando, additional, Consoli, Ugo, additional, Bringhen, Sara, additional, Zamagni, Elena, additional, Patriarca, Francesca, additional, De Stefano, Valerio, additional, Di Raimondo, Francesco, additional, Palmieri, Salvatore, additional, Petrucci, Maria Teresa, additional, Offidani, Massimo, additional, Musto, Pellegrino, additional, Boccadoro, Mario, additional, Cavo, Michele, additional, Neri, Antonino, additional, Morabito, Fortunato, additional, and Gentile, Massimo, additional

Published
2022
Full Text
View/download PDF

15. Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study

Author

Mancuso, Salvatrice, Carlisi, Melania, Serra, Nicola, Napolitano, Mariasanta, Raso, Simona, Consoli, Ugo, Palazzolo, Roberto, Lanza Cariccio, Maria Rosa, Siragusa, Sergio, Mancuso S., Carlisi M., Serra N., Napolitano M., Raso S., Consoli U., Palazzolo R., Cariccio M.R.L., and Siragusa S.

Subjects
immunogeriatrics, aging, immuno-geriatrics, itp treatment, lcsh:RC633-647.5, Immunogeriatric, lcsh:Diseases of the blood and blood-forming organs, Settore MED/15 - Malattie Del Sangue, Journal of Blood Medicine, tpo-receptor agonist, primary immune thrombocytopenia (itp), ITP, Primary immune thrombocytopenia, Original Research
Abstract

Salvatrice Mancuso,1 Melania Carlisi,1 Nicola Serra,2,3 Mariasanta Napolitano,1 Simona Raso,3 Ugo Consoli,4 Roberto Palazzolo,5 Maria Rosa Lanza Cariccio,6 Sergio Siragusa1 1Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) Department, University of Palermo, Palermo, Italy; 2Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples, Italy; 3Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy; 4UOC Ematologia ARNAS Garibaldi, Catania, Italy; 5UOS Ematologia, Asst Valtellina e Alto Lario, Sondrio, Italy; 6Dipartimento Oncologico, La Maddalena, UOC Di Oncoematologia e TMO, Palermo, ItalyCorrespondence: Melania CarlisiHealth Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) Department, University of Palermo, 129 Via del Vespro, Palermo 90127, ItalyTel +39 091-655-4504Fax +39 0916554502Email melania.carlisi@unipa.itPurpose: Insufficient knowledge of primary immune thrombocytopenia purpura (ITP) in the elderly, together with a lack of clinical trial data, has resulted in wide variation in treatments. Here, we present a study focused on clinical characteristics of ITP in older subjects at diagnosis integrated with the subsequent course of the disease and treatment history.Methods: In a retrospective monoinstitutional study, we evaluated > 65-year-old patients with primary ITP. Clinical characteristics at the time of diagnosis were described and analyzed. We aimed to delineate whether subsequent lines of therapy influenced the number of relapses. In addition to initial regimens, we reported subsequent treatments and the impact on relapse trends.Results: A total of 50 patients (56% males, mean age 78 years) were included. With regard to clinical variables at diagnosis, statistical significance was found for Eastern Cooperative Oncology Group performance status 1 (46% of patients, p< 0.0001), presence of three comorbidities (36% of patients, p< 0.0001), World Health Organization grade 0 bleeding (46%, p=0.0001), and World Health Organization grade 1 bleeding (42%, p=0.0009). For bleeding sites, the most frequent were skin or mucosa (40%, p=0.0477). A decrease in platelet count was correlated with moderate or severe bleeding (ρ=− 0.52, p=0.0001) and viscera or skin/mucosa + viscera site (ρ=− 0.50, p=0.0002). Finally, a decreasing number of patients required treatment from first-line therapy to sixth (p< 0.0001). Relapse was most frequent before second-line therapy (54%, p< 0.0001) and less frequent before fivth and sixth (4%, p=0.0072; 2%, p=0.0027).Conclusion: ITP in older age poses considerable challenges, so specific management strategies should be considered to optimize outcomes. Our findings provide evidence of an inverse relationship between lines of therapy and timing of relapses. This study does not exclude the possibility that agents used after first-line therapy may have an impact on the response and modify the unfavorable course of ITP.Keywords: primary immune thrombocytopenia, ITP, immunogeriatrics, Tpo-receptor agonist, ITP treatment, aging

Published
2020

17. Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study

Author

Petrini, Mario, primary, Gaidano, Gianluca, additional, Mengarelli, Andrea, additional, Consoli, Ugo, additional, Santoro, Armando, additional, Liberati, Anna Maria, additional, Ladetto, Marco, additional, Fraticelli, Vincenzo, additional, Guarini, Attilio, additional, Mannina, Donato, additional, Ferrando, Paola, additional, Corradini, Paolo, additional, Musto, Pellegrino, additional, Stelitano, Caterina, additional, Marino, Dario, additional, Camera, Andrea, additional, Murineddu, Marco, additional, Battistini, Roberta, additional, Caparrotti, Giuseppe, additional, Turrini, Mauro, additional, Arcaini, Luca, additional, Santini, Simone, additional, Cerqueti, Manuela, additional, Ferreri, Andres J. M., additional, Cantore, Nicola, additional, Inzoli, Alessandro, additional, Cardinale, Giovanni, additional, Ronci, Benedetto, additional, La Nasa, Giorgio, additional, Massimi, Stefano, additional, Gaglione, Gianfranco, additional, Barbiero, Valentina, additional, and Martelli, Maurizio, additional

Published
2022
Full Text
View/download PDF

18. Immune Thrombotic Thrombocytopenic Purpura following Pfizer-BioNTech anti-COVID-19 vaccination in a patient healed from lymphoma after allogeneic hematopoietic stem cell transplantation

Author

Innao, Vanessa, Urso, Salvatore, Insalaco, Monica, Borraccino, Albino, and Consoli, Ugo

Subjects
Lymphoma, Purpura, Thrombotic Thrombocytopenic, Vaccination, Hematopoietic Stem Cell Transplantation, Letter to the Editors-in-Chief, ADAMTS13 Protein, Humans, Thrombotic microangiopathy, Thrombotic Thrombocytopenic Purpura, Hematology, Covid-19, ADAMTS13
Published
2021

19. Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study

Author

Gentile, Massimo, Cutrona, Giovanna, Molica, Stefano, Ilariucci, Fiorella, Mauro, Francesca R., Di Renzo, Nicola, Di Raimondo, Francesco, Vincelli, Iolanda, Todoerti, Katia, Matis, Serena, Musolino, Caterina, Fabris, Sonia, Lionetti, Marta, Levato, Luciano, Zupo, Simona, Angrilli, Francesco, Consoli, Ugo, Festini, Gianluca, Longo, Giuseppe, Cortelezzi, Agostino, Musto, Pellegrino, Federico, Massimo, Neri, Antonino, Ferrarini, Manlio, and Morabito, Fortunato

Published
2016
Full Text
View/download PDF

20. Mucorales / Fusarium Mixed Infection in Hematologic Patient with COVID-19 Complications: An Unfortunate Combination.

Author

Marino, Andrea, Calvo, Maddalena, Trovato, Laura, Scalia, Guido, Gussio, Maria, Consoli, Ugo, Ceccarelli, Manuela, Nunnari, Giuseppe, and Cacopardo, Bruno

Subjects
FUSARIOSIS, COVID-19, BLOOD diseases, MYCOSES, OPPORTUNISTIC infections, ANTIFUNGAL agents
Abstract

Hematological diseases, especially those causing severe neutropenia, represent the main factor in the development of invasive fungal infections (IFIs). Furthermore, COVID-19 has been considerably associated with IFIs due to immunological dysregulation, prolonged hospitalization in intensive care units, and immunomodulatory therapies. Opportunistic molds are correlated with elevated morbidity and mortality rates in these patients, due to immune impairment, diagnostic complexity, and therapeutic challenges. Among opportunistic fungal infections, the Mucorales and Fusarium species are considered particularly aggressive, especially during severe neutropenia. A mixed Mucorales/Fusarium infection has been rarely described in scientific literature. Herein, we report a case of Mucorales and Fusarium co-infection in a patient with acute leukemia whose clinical history was also complicated by COVID-19. Herein, we report a challenging case in order to encourage the clinical suspicion of combined fungal infections in immunosuppressed patients, performing a punctual microbiological diagnosis, and promptly administering the correct empiric and targeted antifungal therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Nationwide Survey on the Use of Thrombopoietin Receptor Agonists (TPO-RA) for the Management of Immune Thrombocytopenia in Current Clinical Practice in Italy.

Author

Napolitano, Mariasanta, Vianelli, Nicola, Ghiotto, Lisanna, Cantoni, Silvia, Carli, Giuseppe, Carpenedo, Monica, Carrai, Valentina, Consoli, Ugo, Giuffrida, Gaetano, Lucchini, Elisa, Rossi, Elena, Santoro, Cristina, and Rodeghiero, Francesco

Subjects
THROMBOPOIETIN receptor agonists, IDIOPATHIC thrombocytopenic purpura, OLDER patients, BLOOD platelet disorders, ROMIPLOSTIM, ELTROMBOPAG
Abstract

Background: Two thrombopoietin receptor agonists (TPO-RA), romiplostim and eltrombopag, are currently widely adopted as second-line ITP therapy even in the absence of robust evidence on their comparative advantages over rituximab or splenectomy or their preferential use in some specific clinical contexts. Methods: An online survey was distributed between May 2021 and June 2021 to collect standardized information on TPO-RA use in Italy. Results: Eighty-eight hematologists from 79 centers completed the survey. Eighty-four percent would use TPO-RA earlier than formally indicated, without a preference for young or elderly in 82% of respondents. No clear preference for either romiplostim or eltrombopag was indicated. Seventy-two percent would use TPO-RA in young patients aiming at a complete response followed by tapering, a strategy considered by only 16% in the elderly. Switching between the two agents was considered appropriate in case of insufficient response or intolerance. Tapering schedule by reducing the dosage and prolonging the intervals between administrations was preferred by 73% of respondents. TPO-RA was considered a risk factor for thrombosis by only 35%, and 94% would administer TPO-RA in elderly patients also in the presence of other thrombotic risk factors. Thirty-three percent of respondents would withdraw TPO-RA in case of thrombosis. The TPORA administration has been reported to be preferred over anti-CD20 or splenectomy by about half of the participants due to the ongoing COVID-19 pandemic. Conclusions: Significant discrepancies in TPO-RA use emerged from the survey, and participants would appreciate consensus-based specific guidance on the practical use of TPO-RA. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study

Author

Morabito, Fortunato, Cutrona, Giovanna, Gentile, Massimo, Fabris, Sonia, Matis, Serena, Vigna, Ernesto, Todoerti, Katia, Colombo, Monica, Recchia, Anna G., Bossio, Sabrina, De Stefano, Laura, Ilariucci, Fiorella, Cortelezzi, Agostino, Consoli, Ugo, Vincelli, Iolanda, Pesce, Emanuela A., Musolino, Caterina, Molica, Stefano, Di Raimondo, Francesco, Neri, Antonino, and Ferrarini, Manlio

Published
2015
Full Text
View/download PDF

24. Primary spinal Burkitt’s lymphoma: Case report and literature review

Author

Costanzo, Roberta, primary, Scalia, Gianluca, additional, Marrone, Salvatore, additional, Umana, Giuseppe Emmanuele, additional, Giuffrida, Massimiliano, additional, Furnari, Massimo, additional, Salerno, Marilena, additional, Consoli, Ugo, additional, Iacopino, Domenico Gerardo, additional, Nicoletti, Giovanni Federico, additional, and Ponzo, Giancarlo, additional

Published
2021
Full Text
View/download PDF

25. Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia

Author

Palandri, Francesca, Rossi, Elena, Bartoletti, Daniela, Ferretti, Antonietta, Ruggeri, Marco, Lucchini, Elisa, Carrai, Valentina, Barcellini, Wilma, Patriarca, Andrea, Rivolti, Elena, Consoli, Ugo, Cantoni, Silvia, Oliva, Esther Natalie, Chiurazzi, Federico, Caocci, Giovanni, Giuffrida, Gaetano, Borchiellini, Alessandra, Auteri, Giuseppe, Baldacci, Erminia, Carli, Giuseppe, Nicolosi, Daniela, Sutto, Emanuele, Carpenedo, Monica, Cavo, Michele, Mazzucconi, Maria Gabriella, Zaja, Francesco, De Stefano, Valerio, Rodeghiero, Francesco, Vianelli, Nicola, Rossi, Elena (ORCID:0000-0002-7572-9379), De Stefano, Valerio (ORCID:0000-0002-5178-5827), Palandri, Francesca, Rossi, Elena, Bartoletti, Daniela, Ferretti, Antonietta, Ruggeri, Marco, Lucchini, Elisa, Carrai, Valentina, Barcellini, Wilma, Patriarca, Andrea, Rivolti, Elena, Consoli, Ugo, Cantoni, Silvia, Oliva, Esther Natalie, Chiurazzi, Federico, Caocci, Giovanni, Giuffrida, Gaetano, Borchiellini, Alessandra, Auteri, Giuseppe, Baldacci, Erminia, Carli, Giuseppe, Nicolosi, Daniela, Sutto, Emanuele, Carpenedo, Monica, Cavo, Michele, Mazzucconi, Maria Gabriella, Zaja, Francesco, De Stefano, Valerio, Rodeghiero, Francesco, Vianelli, Nicola, Rossi, Elena (ORCID:0000-0002-7572-9379), and De Stefano, Valerio (ORCID:0000-0002-5178-5827)

Abstract

The efficacy and safety of thrombopoietin-receptor agonists (TRAs) in elderly patients with primary immune thrombocytopenia (ITP) is uncertain. In 384 ITP patients treated with TRAs when aged ≥60 years, we investigated TRAs response and switch, thrombotic/hemorrhagic risk, and sustained responses off-treatment (SROT). After 3 months, 82.5% and 74.3% of eltrombopag and romiplostim-treated patients achieved a response, respectively (p=0.09); 66.7% maintained the response (median follow-up: 2.7 years). Eighty-five (22.2%) patients switched to the alternative TRA; while no cross-toxicity was observed, 83.3% of resistant patients had a response after the switch. During TRA, 34 major thromboses (3 fatal) and 14 major hemorrhages (none fatal) occurred in 18 and 10 patients, respectively, and were associated with thrombosis history (SHR: 2.04, p=0.05) and platelet count <20x109/L at TRA start (SHR: 1.69, p=0.04), respectively. A recurrent event occurred in 15.6% of patients surviving thrombosis, in all cases but one during persisting TRA treatment (incidence rate: 7.7 per 100 patient-years). All recurrences occurred in the absence of adequate antithrombotic secondary prophylaxis. Sixty-two (16.5%) responding patients discontinued TRA; 53 (13.8%) patients maintained SROT, which was associated with TRA discontinuation in complete response (p<0.001). Very old age (≥75, 41.1%) was associated with more frequent TRAs start in persistent/acute phase but not with response or thrombotic/hemorrhagic risk. TRAs are effective in elderly ITP patients, with no fatal haemorrhages and with SROT in a significant portion of patients; in patients with thrombosis history caution is warranted and a careful risk/benefit balance should be carried out.

Published
2021

26. Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study

Author

Iannitto, Emilio, Balzarotti, Monica, Martelli, Maurizio, Zinzani, Pier Luigi, Tucci, Alessandra, Di Rocco, Alice, Cavallo, Federica, Usai, Sara, Guidetti, Anna, Ravano, Emanuele, Merli, Franceso, Botto, Barbara, Pelosini, Matteo, Tecchio, Cristina, Spina, Michele, Derenzini, Enrico, Finotto, Silvia, Mola, Brunella, Pinto, Antonio, Zanni, Manuela, Battistini, Roberta, Hohaus, Stefan, Dogliotti, Irene, Gini, Guido, Zilioli, Vittorio Ruggero, De Lorenzo, Sonya, Dodero, Anna, Broccoli, Alessandro, Maggi, Alessandro, Mannarella, Clara, Chiarenza, Annalisa, Pastore, Domenico, Musto, Pellegrino, Stelitano, Caterina, Di Raimondo, Francesco, Cascavilla, Nicola, Di Renzo, Nicola, Salerno, Marilena, Scalone, Renato, Nassi, Luca, Guarini, Attilio, Patti, Caterina, Polizzi, Vita, Amato, Gabriella, Ciccone, Giovannino, Evangelista, Andrea, La Porta, Agostino, Genua, Angelo, Mannina, Donato, Improta, Ciro Maria, Re, Alessandro, Lo Presti, Fabrizio, Calogero, Rosalba Donatella, Musso, Maurizio, and Consoli, Ugo

Published
2023
Full Text
View/download PDF

27. TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Author

Morabito, Fortunato, primary, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Bossio, Sabrina, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Recchia, Anna Grazia, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Al‐Janazreh, Hamdi, additional, Martino, Enrica Antonia, additional, Vigna, Ernesto, additional, Tripepi, Giovanni, additional, D'Arrigo, Graziella, additional, Galimberti, Sara, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Neri, Antonino, additional, Fronza, Gilberto, additional, Cutrona, Giovanna, additional, Jaksic, Ozren, additional, Olivieri, Jacopo, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Cuneo, Antonio, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Trentin, Livio, additional, Foà, Robin, additional, Ferrarini, Manlio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

28. Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trials

Author

Morabito, Fortunato, primary, Tripepi, Giovanni, additional, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Bossio, Sabrina, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Al‐Janazreh, Hamdi, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Cassin, Ramona, additional, D′Arrigo, Graziella, additional, Galimberti, Sara, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Neri, Antonino, additional, Fronza, Gilberto, additional, Monti, Paola, additional, Menichini, Paola, additional, Olivieri, Jacopo, additional, Cutrona, Giovanna, additional, Rossi, Davide, additional, Cuneo, Antonio, additional, Di Raimondo, Francesco, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Trentin, Livio, additional, Foà, Robin, additional, Ferrarini, Manlio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

29. Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia

Author

Palandri, Francesca, primary, Rossi, Elena, additional, Bartoletti, Daniela, additional, Ferretti, Antonietta, additional, Ruggeri, Marco, additional, Lucchini, Elisa, additional, Carrai, Valentina, additional, Barcellini, Wilma, additional, Patriarca, Andrea, additional, Rivolti, Elena, additional, Consoli, Ugo, additional, Cantoni, Silvia, additional, Oliva, Esther Natalie, additional, Chiurazzi, Federico, additional, Caocci, Giovanni, additional, Giuffrida, Gaetano, additional, Borchiellini, Alessandra, additional, Auteri, Giuseppe, additional, Baldacci, Erminia, additional, Carli, Giuseppe, additional, Nicolosi, Daniela, additional, Sutto, Emanuele, additional, Carpenedo, Monica, additional, Cavo, Michele, additional, Mazzucconi, Maria Gabriella, additional, Zaja, Francesco, additional, De Stefano, Valerio, additional, Rodeghiero, Francesco, additional, and Vianelli, Nicola, additional

Published
2021
Full Text
View/download PDF

30. Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study

Author

Mancuso,Salvatrice, Carlisi,Melania, Serra,Nicola, Napolitano,Mariasanta, Raso,Simona, Consoli,Ugo, Palazzolo,Roberto, Lanza Cariccio,Maria Rosa, Siragusa,Sergio, Mancuso,Salvatrice, Carlisi,Melania, Serra,Nicola, Napolitano,Mariasanta, Raso,Simona, Consoli,Ugo, Palazzolo,Roberto, Lanza Cariccio,Maria Rosa, and Siragusa,Sergio

Abstract

Salvatrice Mancuso,1 Melania Carlisi,1 Nicola Serra,2,3 Mariasanta Napolitano,1 Simona Raso,3 Ugo Consoli,4 Roberto Palazzolo,5 Maria Rosa Lanza Cariccio,6 Sergio Siragusa1 1Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) Department, University of Palermo, Palermo, Italy; 2Department of Molecular Medicine and Medical Biotechnology, University Federico II of Naples, Naples, Italy; 3Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, Italy; 4UOC Ematologia ARNAS Garibaldi, Catania, Italy; 5UOS Ematologia, Asst Valtellina e Alto Lario, Sondrio, Italy; 6Dipartimento Oncologico, La Maddalena, UOC Di Oncoematologia e TMO, Palermo, ItalyCorrespondence: Melania CarlisiHealth Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE) Department, University of Palermo, 129 Via del Vespro, Palermo 90127, ItalyTel +39 091-655-4504Fax +39 0916554502Email melania.carlisi@unipa.itPurpose: Insufficient knowledge of primary immune thrombocytopenia purpura (ITP) in the elderly, together with a lack of clinical trial data, has resulted in wide variation in treatments. Here, we present a study focused on clinical characteristics of ITP in older subjects at diagnosis integrated with the subsequent course of the disease and treatment history.Methods: In a retrospective monoinstitutional study, we evaluated > 65-year-old patients with primary ITP. Clinical characteristics at the time of diagnosis were described and analyzed. We aimed to delineate whether subsequent lines of therapy influenced the number of relapses. In addition to initial regimens, we reported subsequent treatments and the impact on relapse trends.Results: A total of 50 patients (56% males, mean age 78 years) were included. With regard to clinical variables at diagnosis, statistical significance was found for Eastern Cooperative Oncology Group performance status 1 (46% of p

Published
2020

31. Assessment of the 4‐factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

Author

Morabito, Fortunato, primary, Tripepi, Giovanni, additional, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Mendicino, Francesco, additional, Botta, Cirino, additional, Caracciolo, Daniele, additional, Cassin, Ramona, additional, D'Arrigo, Graziella, additional, Galimberti, Sara, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Neri, Antonino, additional, Fronza, Gilberto, additional, Cutrona, Giovanna, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Cuneo, Antonio, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Trentin, Livio, additional, Foà, Robin, additional, Ferrarini, Manlio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

32. Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia cases

Author

Morabito, Fortunato, primary, Tripepi, Giovanni, additional, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Bossio, Sabrina, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Visentin, Andrea, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Al‐Janazreh, Hamdi, additional, Vigna, Ernesto, additional, Martino, Enrica Antonia, additional, Mendicino, Francesco, additional, Cassin, Ramona, additional, D'Arrigo, Graziella, additional, Galimberti, Sara, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Neri, Antonino, additional, Fronza, Gilberto, additional, Monti, Paola, additional, Menichini, Paola, additional, Cutrona, Giovanna, additional, Jaksic, Ozren, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Cuneo, Antonio, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Trentin, Livio, additional, Foà, Robin, additional, Ferrarini, Manlio, additional, Gattei, Valter, additional, and Gentile, Massimo, additional

Published
2021
Full Text
View/download PDF

34. Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia

Author

Fabris, Sonia, Mosca, Laura, Cutrona, Giovanna, Lionetti, Marta, Agnelli, Luca, Ciceri, Gabriella, Barbieri, Marzia, Maura, Francesco, Matis, Serena, Colombo, Monica, Gentile, Massimo, Recchia, Anna Grazia, Anna Pesce, Emanuela, Di Raimondo, Francesco, Musolino, Caterina, Gobbi, Marco, Di Renzo, Nicola, Mauro, Francesca Romana, Brugiatelli, Maura, Ilariucci, Fiorella, Lipari, Maria Grazia, Angrilli, Francesco, Consoli, Ugo, Fragasso, Alberto, Molica, Stefano, Festini, Gianluca, Vincelli, Iolanda, Cortelezzi, Agostino, Federico, Massimo, Morabito, Fortunato, Ferrarini, Manlio, and Neri, Antonino

Published
2013
Full Text
View/download PDF

35. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study

Author

Gentile, Massimo, primary, Morabito, Fortunato, additional, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Recchia, Anna Grazia, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Fraticelli, Vincenzo, additional, Vigna, Ernesto, additional, Botta, Cirino, additional, Tripepi, Giovanni, additional, Arrigo, Graziella D’, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Rigolin, Gian Matteo, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Cuneo, Antonio, additional, Foà, Robin, additional, and Gattei, Valter, additional

Published
2020
Full Text
View/download PDF

36. Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real‐world study

Author

Iannitto, Emilio, primary, Romano, Alessandra, additional, Scalzulli, Potito Rosario, additional, Bonanno, Vincenza, additional, Scalone, Renato, additional, Chiarenza, Annalisa, additional, Pirosa, Maria Cristina, additional, Caruso, Anastasia Laura, additional, Minoia, Carla, additional, Mantuano, Saverio, additional, De Santis, Gaetano, additional, Salerno, Marilena, additional, Crescimanno, Alessandra, additional, Porretto, Ferdinando, additional, Li Gioi, Felicina, additional, Ricciuti, Giuseppina, additional, Greco, Antonino, additional, Pavone, Enzo, additional, Guarini, Attilio, additional, Tarantini, Giuseppe, additional, Mannina, Donato, additional, Consoli, Ugo, additional, Cascavilla, Nicola, additional, Di Raimondo, Francesco, additional, and Musso, Maurizio, additional

Published
2020
Full Text
View/download PDF

39. Multidrug resistance mechanisms in chronic lymphocytic leukaemia

Author

Consoli, Ugo, Santonocito, AnnaMaria, Stagno, Fabio, Fiumara, Paolo, Privitera, Antonella, Parisi, Giuseppina, Giustolisi, Giada M, Pavone, Biagia, Palumbo, Giuseppe A, Di Raimondo, Francesco, Milone, Giuseppe, Guglielmo, Patrizia, and Giustolisi, Rosario

Published
2002

44. External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study

Author

Gentile, Massimo, primary, Morabito, Fortunato, additional, Del Poeta, Giovanni, additional, Mauro, Francesca Romana, additional, Reda, Gianluigi, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Herishanu, Yair, additional, Recchia, Anna G, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Rossi, Francesca Maria, additional, Zucchetto, Antonella, additional, Vigna, Ernesto, additional, Tripepi, Giovanni, additional, Rago, Angela, additional, Angeletti, Ilaria, additional, Biagi, Annalisa, additional, Del Giudice, Ilaria, additional, Bomben, Riccardo, additional, Rigolin, Gian Matteo, additional, Rossi, Davide, additional, Di Raimondo, Francesco, additional, Gaidano, Gianluca, additional, Polliack, Aaron, additional, Cuneo, Antonio, additional, Foà, Robin, additional, and Gattei, Valter, additional

Published
2019
Full Text
View/download PDF

45. Preliminary Results of a Prospective Observational Study to Assess the Prevalence of Gaucher Disease in an Adult Population Affected By MGUS

Author

Giuffrida, Gaetano, primary, Conticello, Concetta, additional, Nicolosi, Daniela, additional, Calafiore, Valeria, additional, Romano, Alessandra, additional, Consoli, Ugo, additional, Musolino, Caterina, additional, Innao, Vanessa, additional, Fiorenza, Flavia, additional, Maugeri, Cinzia, additional, Longo, Giuseppe, additional, Cingari, Maria Rocca, additional, and Di Raimondo, Francesco, additional

Published
2019
Full Text
View/download PDF

46. Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and Rituximab

Author

Gentile, Massimo, primary, Reda, Gianluigi, additional, Mauro, Francesca Romana, additional, Sportoletti, Paolo, additional, Laurenti, Luca, additional, Coscia, Marta, additional, Recchia, Anna G, additional, Varettoni, Marzia, additional, Murru, Roberta, additional, Chiarenza, Annalisa, additional, Condoluci, Adalgisa, additional, Moia, Riccardo, additional, Pietrasanta, Daniela, additional, Loseto, Giacomo, additional, Consoli, Ugo, additional, Scortechini, Ilaria, additional, Vigna, Ernesto, additional, Botta, Cirino, additional, Fraticelli, Vincenzo Ludovico, additional, Di Prima, Alessio, additional, Tripepi, Giovanni, additional, Rossi, Davide, additional, Gaidano, Gianluca, additional, Gattei, Valter, additional, and Morabito, Fortunato, additional

Published
2019
Full Text
View/download PDF

47. Real-Rd - Real Life Italian Experience with Lenalidomide and Low-Dose Dexamethasone (Rd) As First Line Treatment of Newly-Diagnosed Multiple Myeloma Patients Not Eligible to Stem Cell Transplantation: Outcomes and Tolerability

Author

Pompa, Alessandra, primary, Conticello, Concetta, additional, Giannarelli, Diana, additional, Pettine, Loredana, additional, Paris, Laura, additional, Tognazzi, Lucia, additional, Marcatti, Magda, additional, Antonioli, Elisabetta, additional, Fioritoni, Francesca, additional, Bonalumi, Angela, additional, Mangiacavalli, Silvia, additional, Bertazzoni, Paola, additional, Vincelli, Iolanda Donatella, additional, Derudas, Daniele, additional, Siniscalchi, Agostina, additional, Pezzatti, Sara, additional, Zambello, Renato, additional, Citro, Annalisa, additional, Belotti, Angelo, additional, Lombardo, Alessandra, additional, Vozella, Federico, additional, Sementa, Adelina, additional, Consoli, Ugo, additional, Molteni, Alfredo, additional, Frungillo, Niccolò, additional, Gentile, Massimo, additional, Buda, Gabriele, additional, Aquino, Sara, additional, Palmieri, Salvatore, additional, Bongarzoni, Velia, additional, Inzoli, Alessandro, additional, Ferla, Valeria, additional, Rossi, Francesca Gaia, additional, Leotta, Valerio, additional, Romano, Alessandra, additional, Elia, Federica, additional, Del Fabro, Vittorio, additional, Montanaro, Guido, additional, Cavallaro, Francesca, additional, Galli, Monica, additional, and Baldini, Luca, additional

Published
2019
Full Text
View/download PDF

48. Real‐world experience with decitabine as a first‐line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy

Author

Bocchia, Monica, primary, Candoni, Anna, additional, Borlenghi, Erika, additional, Defina, Marzia, additional, Filì, Carla, additional, Cattaneo, Chiara, additional, Sammartano, Vincenzo, additional, Fanin, Renato, additional, Sciumè, Margherita, additional, Sicuranza, Anna, additional, Imbergamo, Silvia, additional, Riva, Marta, additional, Fracchiolla, Nicola, additional, Latagliata, Roberto, additional, Caizzi, Emanuela, additional, Mazziotta, Francesco, additional, Alunni, Giulia, additional, Di Bona, Eros, additional, Crugnola, Monica, additional, Rossi, Marianna, additional, Consoli, Ugo, additional, Fontanelli, Giulia, additional, Greco, Giuseppina, additional, Nadali, Gianpaolo, additional, Rotondo, Francesco, additional, Todisco, Elisabetta, additional, Bigazzi, Catia, additional, Capochiani, Enrico, additional, Molteni, Alfredo, additional, Bernardi, Massimo, additional, Fumagalli, Monica, additional, Rondoni, Michela, additional, Scappini, Barbara, additional, Ermacora, Anna, additional, Simonetti, Federico, additional, Gottardi, Michele, additional, Lambertenghi Deliliers, Daniela, additional, Michieli, Mariagrazia, additional, Basilico, Claudia, additional, Galeone, Carlotta, additional, Pelucchi, Claudio, additional, and Rossi, Giuseppe, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results